eGreen BiotekStock code: 7525
Home/Make data visible and provide evidence-based interpretation.

SCIENCE / RESEARCH DATA EXPLORER

See the data.
Understand the evidence.

From culture output, chemical experiments to human observation, read the materials, units, comparison groups and limitations of each picture one by one. The numerical diagram is redrawn based on the source report; the research context is also organized using a classification matrix, experimental design and mechanism process.

Original eGreen laboratory-work photograph showing a gloved operator using a multichannel pipette and microplate
Laboratory work

HOW TO USE THE DATA EXPLORER

Read the conditions before the numbers.

Each study is presented separately. Interpret scales, units and sample definitions within the source study; different models do not form an efficacy ranking.

Research topicsCurated research recordsStudies & evidence

The following are external studies, not eGreen test results. Each graph answers a different question, and the values ​​are not directly comparable across studies; the materials, concentrations, and doses in the graphs are only used to explain the study conditions.

Download chart data CSV

RESEARCH LANDSCAPE

Topic × Evidence,
See research distribution at a glance.

The darker the color, the more records are included on this site; it does not mean better efficacy or stronger evidence. Click on the number to directly read the corresponding document.

Topic tag distribution of 29 materials on this site (can be repeated across topics)
Research topicsHuman intervention / observationCaseRegistryanimalscellsAcademic thesisProcessIngredientsSpecies
Cancer & Tumors32—35—2——
Immune Modulation3——2—1———
Skin & Allergy21———————
Metabolism & Glucose———111———
Gut & Microbiome———4—————
Liver Injury———1—————
Neuronal Cell Protection————1————
Exercise & Fatigue——1——————
Safety Signals21———————
Species, Chemistry & Processing————41211

"—" means that this selection is not included, but it does not mean that there is no research in this field. Narrow screens allow the table to be scrolled left and right. The Human Body column contains 1 study of P. igniarius related taxa.

Download complete document classification CSV

HUMAN EVIDENCE, IN CONTEXT

A growing body of human research.
Each study design matters.

A total of 11 data involving human subjects: 7 interventional/observational studies, 3 case reports, and 1 trial registration. 1 of the randomized studies used a different species, P. igniarius, and was labeled independently.

Randomized controlled2 + 1

2 studies on PL immunity; another 1 study on P. igniarius related taxa.

Explore studies →Retrospective cohorts2

Postoperative observation of pancreatic cancer; samples from the same hospital and year partially overlap, so samples cannot be combined.

Explore studies →Pre–post observation2

Atopic dermatitis; the abstract does not describe a randomized parallel trial.

Explore studies →Case reports3

Prostate Cancer, Liver Cancer and Safety Letter; Not an Efficacy Trial.

Explore studies →Trial registry1

Taiwan fatigue resistance study; completed, results not yet posted.

Explore studies →

The number is the number of records, not the evidence strength score, nor the total number of patients. Endpoints such as immunity, symptoms, and survival are not substitutes for each other.

View dermatitis pre- and post-test charts

06 / ATOPIC DERMATITIS · 2008

35 people, observed before and after 12 weeks [R16]

Symptom score changes,
do not establish a controlled treatment effect.

Patients with atopic dermatitis aged 2–14 years; germinated brown rice culture PL material. The averages are replotted below based on journal abstracts, using their own scales for both indicators.

Objective SCORAD

02040Score (display range 0–40)Baseline 25.31Week 12: 18.73

Tickling VAS

0510Score (display range 0–10)Baseline 7.37Week 12: 4.6

The connection only connects the two averages and does not represent individual patient trajectories. Summary not clarified ± Figures are SD or SE, so error bars are not drawn; not zero variation.

View source values & limitations
IndicatorBefore intervention12 weeksbefore and after comparison
Objective SCORAD25.31 ± 8.9618.73 ± 13.89p < 0.05
Tickling VAS7.37 ± 1.334.60 ± 2.30p < 0.05

The abstract does not describe a parallel control group; natural disease history and other influences cannot be excluded. The figure does not convert "improvement rate", nor does it estimate the effect of eGreen materials.

Research abstracts and journal sources [R16]

07 / TAIWAN HUMAN TRIAL REGISTRY

Official registry · no results posted [R27]

58 people, 42 days.
Read and study how to design first.

58Actual number of people included
42Intervention days
2Randomized double-blind group
  1. Day 0Baseline Assessment
    CK、IMTP
  2. Day 21Mid-term evaluation
    CK
  3. Day 42Late intervention period
    CK、IMTP

CK is also planned to be followed 3, 24, and 48 hours after exhaustive exercise. The figure shows the time point of the plan, and no results that have not yet been announced are included.

Completed · Actual completion 2025-10-21
Latest update 2026-04-13 · Results not posted

National Sports University SS-MN4 mycelium study; completion status is not a conclusion of validity. Data verification date 2026-10-02.

Official registry & study design [R27]

09 / MICROBIOME MECHANISM · 2024

DSS enteritis mice・Mechanism diagram [R23]

From bacterial association to path testing.

  1. Research MaterialsSanghuang polyphenol extractSanghuangporus extract
  2. Microbiota cluesA. onderdonkiiInvolvement of intestinal bacteria
  3. Metabolites5-HIAAMetabolic Signal Under Research
  4. receptor pathwayAhRTest participation with antagonists
  5. Model ObservationEnteritis related indicatorsDSS mouse model

Study the addition of strains, metabolite intervention and AhR blocking experiments to strengthen the evidence of pathway involvement. The mechanism chain proposed by the arrow-organized research is not a complete causal path that has been confirmed in the human body.

Read iMeta original research [R23]

01 / CULTURE & PRODUCTION · 2025

Culture process research [R8]

Culture conditions change ingredient output.

PL static culture for 30 days, 400 μM VPA intervention; each indicator’s own control group is set to 100.

Hispolon Output Index

Control
100
VPA group
220

Mycelial dry weight index

Control
100
VPA group
141

0–240 common scale; 100 → 220 corresponds to an increase of 120%, and 100 → 141 corresponds to an increase of 41%. This is a relative index, not the original concentration, nor the efficacy.

View source values & units
IndicatorComparison indexIntervention IndexSummary report growth
Hispolon100220+120%
Dry weight of mycelium100141+41%

Follow-up questions: residue and purification, batch reproduction, and quantification of active ingredients. VPA study conditions do not represent the company's current manufacturing processes.

Research abstract and original text [R8]

02 / STRAIN COMPARISON · 2024

Chemical antioxidant test [R10]

How are strain differences reflected in the test?

DPPH radical scavenging EC50 of exopolysaccharides from three strains of S. sanghuang; in this assay, lower values indicate lower concentrations required to achieve the same degree of scavenging.

MS-1
0.273
MS-3
0.291
MS-7
0.08

Horizontal axis scale 0–0.35 mg/mL. Bar lengths are average values; ± values ​​reported in the original article are listed in the data table, and error bars are not drawn in the figure.

View source values & units
strainEC50（mg/mL）
MS-10.273 ± 0.0071
MS-30.291 ± 0.0025
MS-70.080 ± 0.00229

DPPH is a chemical reaction test; a lower EC50 cannot be interpreted as a better anti-cancer effect in the human body.

Research abstract and original text [R10]

03 / HUMAN OBSERVATION · 2025

Retrospective study [R3]

In addition to point estimates, we also need to look at uncertainty.

407 people receiving adjuvant chemotherapy after pancreatic cancer surgery: 103 users of the study PL preparation and 304 non-users.

Study product used/not used; not randomized.

HR 0.6140.20.51.01.2No-effect reference

The endpoint is overall survival (OS). The HR axis uses a logarithmic scale from 0.2 to 1.2; 95% CI 0.376–1.002, p = 0.051.

View source values & units
Projectnumerical value
Number of samples407（103 / 304）
Overall survival (OS) adjusted HR0.614
95% CI0.376–1.002
p-value0.051

The interval contains 1, which does not reach the commonly used 0.05 significance threshold. Point estimates cannot be translated into proven reductions in mortality risk; there are confounding factors in retrospective data.

Read the full interpretation [R3]

04 / PRECLINICAL TUMOR MODEL · 2023

Mouse tumor model [R11]

Results in model, preserving model boundaries.

67.4%

Tumor growth inhibition rate reported in original abstract

U14 xenograft tumor400 mg/kg21 days

S. baumii aqueous extract SHWE; study linking autophagy, intestinal bacteria and tumor response.

View source values & units
ProjectResearch conditions
MaterialS. baumii aqueous extract
animalsFemale Kunming mouse
Condition400 mg/kg, 21 days
Report inhibition rate67.4%

It is not the success rate of human treatment; it is not converted into patient dosage, nor is it ranked with the percentage of different tumor models.

Research abstract and original text [R11]

05 / STUDY DESIGN · 2022

Human immunity test [R4 / R7]

This is also human research, so the question still needs to be clarified.

30Human randomized pilot trialThree groups · 26 people completed [R4]
98Human randomized controlled trialTwo groups · 8-week intervention [R7]
View source values & units
Researchrandom number of peopleNumber of people completedNumber of groupsIntervention period
R4302638 weeks
R798See original text28 weeks

Two studies evaluated immune function, with R7 using NK cell activity as the primary endpoint. The sample size is information about the study design, not the effect size.

Neither article is a cancer treatment trial. Research materials and ethnic groups must be read separately and should not be combined into one trial just because they are published in the same year.

Reading human studies [R7]

How to enter the information on this page?

Only values ​​that can be verified from the original text or original summary are redrawn; coordinates are not estimated from the image, and missing error values ​​are not made up. The relative index clearly lists the conversion rules, and the effects are not combined across trials. Each figure can be expanded into a table and linked back to the research abstract.